Aurinia Pharmaceuticals (NASDAQ:AUPH) & Endo International (NASDAQ:ENDP) Financial Review

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Endo International (NASDAQ:ENDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Earnings and Valuation

This table compares Aurinia Pharmaceuticals and Endo International’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aurinia Pharmaceuticals $460,000.00 965.40 -$64.12 million ($0.76) -6.20
Endo International $2.95 billion 0.37 -$1.03 billion $2.89 1.69

Aurinia Pharmaceuticals has higher earnings, but lower revenue than Endo International. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aurinia Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Endo International has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

31.1% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Endo International shares are held by institutional investors. 1.5% of Endo International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Aurinia Pharmaceuticals and Endo International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals -13,231.97% -50.08% -40.69%
Endo International -19.98% -129.30% 5.75%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Aurinia Pharmaceuticals and Endo International, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 0 7 0 3.00
Endo International 2 10 2 0 2.00

Aurinia Pharmaceuticals presently has a consensus target price of $16.50, indicating a potential upside of 250.32%. Endo International has a consensus target price of $7.58, indicating a potential upside of 55.38%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Endo International.


Endo International beats Aurinia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with's FREE daily email newsletter.